HEALTHWAY MEDICAL CORPORATION LIMITED
Registration No.: 200708625C

PROFIT WARNING FOR THE FOURTH QUARTER ENDED 31 DECEMBER 2016 ("4Q2016") AND FINANCIAL YEAR ENDED 31 DECEMBER 2016 ("FY2016")

The Board of Directors of Healthway Medical Corporation Limited (the "**Company**" and together with its subsidiaries, the "**Group**") wishes to inform the shareholders of the Company that the Group expects to record a loss for 4Q2016 and FY2016. The loss is mainly attributable to the significant impairment of certain receivables, as well as goodwill.

This announcement is based on a preliminary review of the unaudited management accounts of the Group for 4Q2016 and FY2016. Further details of the Group's financial performance will be disclosed when the unaudited financial results for 4Q2016 and FY2016 are announced on or before 1 March 2017.

In the meantime, the Board wishes to advise shareholders of the Company and investors to exercise caution when dealing in the shares of the Company ("**Shares**") and to refrain from taking any action in relation to their Shares which may be prejudicial to their interests. Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors, accountants, tax advisers or other professional advisers immediately.

Shareholders and potential investors should note that the contents of this announcement has not been reported on pursuant to the requirements of Rule 25 of the Singapore Code on Take-overs and Mergers ("Code"). The auditor or reporting accountant report and financial adviser report for this announcement as required by the Code will be published as soon as possible, but no later than the date of the offeree circular to be despatched to shareholders of the Company in accordance with the Code.

Responsibility Statement

The Directors of the Company (including those who have delegated detailed supervision of this announcement) have taken all reasonable care to ensure that the facts stated and all opinions expressed in this announcement are fair and accurate, and that there are no material facts not contained in this announcement, the omission of which would make any statement in this announcement misleading, and they jointly and severally accept responsibility accordingly.

Where any information has been extracted or reproduced from published or otherwise publicly available sources, the sole responsibility of the Directors of the Company has been to ensure through reasonable enquiries that such information is accurately extracted from such sources or, as the case may be, accurately reflected or reproduced in this announcement.

BY ORDER OF THE BOARD

Veronica Chan Wee Ping
President
15 February 2017

*This announcement has been prepared by Healthway Medical Corporation Limited (the "**Company**") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement,*

including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.